Precipio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Precipio şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.9%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost

Aug 21

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Jun 07

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Jun 12

Precipio shares surge on HemeScreen Anemia Panel launch

Jun 08

Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia

May 10

Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke

May 05

Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform

May 03

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PRPO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PRPO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Precipio Piyasaya Karşı Temettü Getirisi

PRPO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PRPO)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Healthcare)	1.6%
Analist tahmini (PRPO) (3 yıla kadar)	n/a

Önemli Temettü: PRPO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PRPO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PRPO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PRPO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Precipio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)

Precipio Expands Bloodhound MPN Panel by Adding CALR Mutation Subtyping

Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost

Second quarter 2024 earnings released: US$0.83 loss per share (vs US$1.88 loss in 2Q 2023)

New minor risk - Share price stability

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

First quarter 2024 earnings released: US$1.46 loss per share (vs US$2.61 loss in 1Q 2023)

New major risk - Financial position

Precipio, Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: US$4.51 loss per share (vs US$10.73 loss in FY 2022)

Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)

Precipio, Inc. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An Opportunity

Consensus revenue estimates increase by 11%

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Market cap size

New minor risk - Share price stability

Precipio, Inc.'s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings released: US$0.54 loss per share (vs US$0.40 loss in FY 2021)

Price target decreased to US$4.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Precipio Receives Noncompliance Letter from the Nasdaq

Precipio, Inc. Appoints Sharon Robins as its Senior Director of Laboratory & Hospital Sales for the Product’s Division

Precipio, Inc. Launches New 1-Step Technology for All Hemescreen Assays

Second quarter 2022 earnings released: US$0.094 loss per share (vs US$0.14 loss in 2Q 2021)

Precipio, Inc. Welcomes Toni-Ann Mills as its Senior Director for Learning & Development

Forecast to breakeven in 2023

Precipio to distribute HemeScreen through Fisher Healthcare channel

Precipio, Inc. Appoints Keith Meadors as Senior Vice President of its Products Division

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Precipio Signs First IV-Cell Customer Agreement

Price target decreased to US$4.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Precipio, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2020)

Precipio terminates its equity line with Lincoln Park

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Precipio, Inc. Launches Hemescreen® Anemia Panel, One-Of-Its-Kind Testing Tool

Precipio shares surge on HemeScreen Anemia Panel launch

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.78 loss in 1Q 2020)

Precipio, Inc. Launches New Hemescreen Panel for AML, with an Unparalleled 4-Hour Turnaround-Time

Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia

Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke

Precipio, Inc. Launches Rapid COVID-19 Antibody Test on Amazon Platform

Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform

Price target increased to US$7.00

Precipio, Inc. to Report Q4, 2020 Results on Mar 31, 2021

Precipio, Inc. Announces Board and Committee Changes

Precipio Launches COVID-19 Antibody Testing at Point-of-Care

Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups

Precipio, Inc. Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor

Precipio & ADS Biotec Launch Seven Beta Sites for IV-Cell™

Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel

Precipio, Inc.(NasdaqCM:PRPO) dropped from Russell Microcap Value Index

Precipio, Inc.(NasdaqCM:PRPO) dropped from Russell Microcap Index

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin